![]() |
Çѱ¹À¯³ªÀÌÆ¼µåÁ¦¾àÀº Áö³ 9ÀÏ Çʸ®ÇÉ ¸¶´Ò¶ó ÄÜ·¡µå È£ÅÚ¿¡¼ ‘°¡½ºÆ¼ÀÎCR’ ½ÉÆ÷Áö¾öÀ» °³ÃÖÇß´Ù°í 15ÀÏ ¹àÇû´Ù. ‘Latest Update in Gastric Motility Disorder and Treatment’ ÀÇ ÁÖÁ¦·Î ¿¸° Çà»ç¿¡´Â Çʸ®ÇÉ ¼Òȱ⳻°ú Àü¹®ÀǸ¦ Æ÷ÇÔÇÏ¿© ÇöÁö ÀÇ·áÁø ¾à450¿©¸íÀÌ Âü¼®ÇÏ¿´´Ù.
À̹ø ½ÉÆ÷Áö¾öÀÇ ¿¬ÀÚ´Â °³²¼¼ºê¶õ½ºº´¿ø À±¿µÈÆ ±³¼ö, ÁÂÀåÀº Diana Alcantara-Payawal (Philippine College of Physician ȸÀå) ±³¼ö°¡ ¸Ã¾ÒÀ¸¸ç, À§Àå°ü¿îµ¿ÃËÁøÁ¦(Prokinetics) Áß Mosapride ÀÓ»ó ¾à¸® È¿°ú, ¾ÈÀü¼º ±×¸®°í °¡½ºÆ¼ÀÎ CR 1ÀÏ 1ȸ ¿ë¹ýÀ¸·Î¼ÀÇ º¹¿ë Æí¸®¼º ¹× ¼øÀÀµµ¿¡ ´ëÇÑ ¹ßÇ¥·Î ÁøÇàµÇ¾ú´Ù.
ÇÑÆí Çѱ¹À¯³ªÀÌÆ¼µåÁ¦¾àÀº ÀÛ³â 5¿ù Çʸ®Çɽľàû (The Philippines FDA)·ÎºÎÅÍ °¡½ºÆ¼ÀÎCR¿¡ ´ëÇÑ Ç°¸ñÇã°¡¸¦ ȹµæÇßÀ¸¸ç, MosaprideÀÇ CRÁ¦Á¦·Î´Â Çѱ¹À¯³ªÀÌÆ¼µåÁ¦¾àÀÇ ‘°¡½ºÆ¼ÀÎCR’ÀÌ À¯ÀÏÇÏ´Ù.
ȸ»ç´Â 3³â³» Çʸ®ÇÉ Mosapride ±â¹Ý Á¦Ç° ½ÃÀåÀÇ 50% ÀÌ»óÀ» Á¡À¯ÇØ ½ÃÀå 1À§ ´Þ¼ºÀ» ¸ñÇ¥·Î Çϰí ÀÖ´Ù.
±èÅÂ¿Ï ±âÀÚ kmedinfo@hanmail.net